Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAnthem Datroway Coverage & Prior Auth Update | Ope…
    Ask Trek AI about this page
    CurrentAnthemPolicy CC-0279

    Datroway (datopotamab deruxtecan-dlnk) — Medical Drug Clinical Criteria

    Customize your policy alerts

    Sign up for Anthem Policy CC-0279 alerts

    Get alerted when Policy CC-0279 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical criteria governing prior authorization and medical necessity determinations for Datroway for adults with unresectable or metastatic HR-positive, HER2-negative breast cancer and for certain EGFR‑mutated NSCLC patients; affects providers seeking coverage under Anthem medical benefit plans.

    Policy Summary
    PayerAnthem
    PolicyDatroway (datopotamab deruxtecan-dlnk) — Medical Drug Clinical Criteria
    Policy CodePolicy CC-0279
    Change TypeAdded EGFR‑mutated NSCLC indicationcoding updates
    Effective Date03/26/2026
    Last ReviewFeb 20, 2026
    Next Review Date
    Key ActionObtain prior authorization and submit documentation showing diagnosis, HER2 and/or EGFR biomarker results, and required prior therapies.
    SourceLink
    POLICY UPDATE CHANGES

    Added FDA indication for use in EGFR-mutated NSCLC in locally advanced or metastatic disease in those with prior EGFR and platinum based chemotherapy.

    Wording and formatting criteria changes during annual review.

    Coding update replacing prior HCPCS/NOC codes and consolidating to J9011 as the HCPCS code for Datroway.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2FDA/NCCN-supported indications listed
    1Current HCPCS code
    3HER2 IHC categories
    1Active brain metastases exclusion

    Coverage Criteria

    Approval criteria (Initial therapy and indications)

    Requests for Datroway may be approved when ALL of the following grouped criteria are met (logical structure preserved):

    Pediatric indication: Individual is under 19 years of age

    Allows approval for patients under 19.

    HR+ HER2- Metastatic/Unresectable Breast Cancer: Individual has a diagnosis of unresectable or metastatic HER2-negative breast cancer (IHC 0 OR IHC 1+ OR IHC 2+/ISH negative), AND has hormone-receptor positive (HR+) disease, AND has received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease

    Based on Label and NCCN 2A.

    EGFR-mutated NSCLC: Individual has a diagnosis of locally advanced or metastatic EGFR-mutated non-small cell lung cancer, AND has received prior EGFR-directed therapy and platinum-based chemotherapy

    Based on Label and NCCN 2A.

    Requests for Datroway will not be approved when the individual has clinically active brain metastases. Active brain metastases are an explicit exclusion to coverage and represent a denial risk for prior authorization requests.

    Requests that do not meet the specified clinical criteria for the listed indications are not approved (not medically necessary). If the documented condition, biomarker status, prior therapies, or other required criteria are not satisfied as outlined in the policy, coverage should be denied.

    Covered Regimens (per label)

    RegimenIndicationCoverage
    Datroway (datopotamab deruxtecan-dlnk)
    Unresectable or metastatic, hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease
    Covered with criteria
    RegimenIndicationCoverage
    Datroway (datopotamab deruxtecan-dlnk)
    Locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-mutated disease in individuals who have received prior EGFR-directed therapy and platinum-based chemotherapy
    Covered with criteria

    Coding

    HCPCSHCPCSCovered
    J9011Injection, datopotamab deruxtecan-dlnk, 1 mg [Datroway]
    ICD-10 DiagnosisICD-10
    C33Malignant neoplasm of trachea
    C34.00-C34.92Malignant neoplasm of bronchus and lung
    C50.011-C50.A2Malignant neoplasm of breast
    Z17.411Hormone receptor positive with human epidermal growth factor receptor 2 negative status [HR+ with HER2-]
    Z92.21Personal history of antineoplastic chemotherapy
    inv-06: HER2 IHC/ISH thresholds
    HER2 IHC categoriesIHC 0, IHC 1+, IHC 2+ (with ISH negative) vs IHC 3+ or ISH positive
    IHC 3+ (Positive) definitionCircumferential membrane staining that is complete, intense in >10% of invasive tumor cells (homogeneous/contiguous)
    IHC 2+ (Equivocal) definitionCircumferential membrane staining that is incomplete and/or weak/moderate in >10% of invasive tumor cells, or complete/intense staining in ≤10% of cells; requires ISH for resolution
    ISH positive thresholdsSingle-probe average HER2 ≥6.0 signals/cell OR dual-probe HER2/CEP17 ratio ≥2.0 with average HER2 ≥4.0 signals/cell OR dual-probe ratio <2.0 with average HER2 ≥6.0 signals/cell
    ISH negative thresholdsSingle-probe average HER2 <4.0 signals/cell OR dual-probe HER2/CEP17 ratio <2.0 with average HER2 <4.0 signals/cell

    Provider Actions & Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Approval is granted only when the clinical criteria for the specified indication are met (breast cancer or EGFR‑mutated NSCLC).

    • Prior authorization required for Datroway (datopotamab deruxtecan‑dlnk).
    • Approval granted only when ALL applicable clinical criteria for the requested indication are satisfied.
    Documentation Required

    Required Clinical Documentation

    Document the diagnosis and supporting clinical information demonstrating the requested indication and prior treatments.

    • For unresectable or metastatic HER2‑negative breast cancer: submit pathology/HER2 testing results showing IHC 0, IHC 1+, or IHC 2+ with negative ISH as appropriate.
    • Include documentation that disease is HR+ (hormone receptor positive).

    Line of Therapy Requirements

    after prior endocrine-based therapy and chemotherapy

    Covered when the following prior therapy requirement is satisfied:

    Breast cancer prior therapy: Received prior endocrine-based therapy and chemotherapy for unresectable or metastatic HR+ breast cancer

    Required prior lines before Datroway use.

    after prior EGFR-directed therapy and platinum chemotherapy

    Covered when the following prior therapy requirement is satisfied:

    NSCLC prior therapy: Received prior EGFR-directed therapy and platinum-based chemotherapy for locally advanced or metastatic EGFR-mutated NSCLC

    Required prior lines before Datroway use.

    Biomarker & Testing Requirements

    inv-17: HER2 (IHC/ISH)
    HER2-negative definition for breast cancer eligibilityIHC 0 OR IHC 1+ OR IHC 2+ with ISH negative
    Source indication contextUsed to determine eligibility for Datroway in unresectable or metastatic HR+, HER2- breast cancer
    Documentation requirementProvide HER2 testing results (IHC and, if applicable, ISH) showing IHC 0, 1+ or 2+/ISH-
    inv-18: EGFR mutation
    EGFR mutation requirementPresence of an EGFR-mutated tumor is required for the NSCLC indication
    Indication contextApplies to locally advanced or metastatic NSCLC being considered for Datroway

    Definitions

    inv-13: HER2 testing definitions
    HER2 positive (per ASCO/CAP)IHC 3+ defined by complete, intense circumferential membrane staining in >10% of invasive tumor cells; or ISH positive per specified copy number/ratio thresholds
    HER2 equivocalIHC 2+ (incomplete and/or weak/moderate staining in >10% of invasive tumor cells or complete/intense in ≤10%) or ISH equivocal (single-probe average HER2 ≥4.0 and <6.0 signals/cell or dual-probe ratio <2.0 with average HER2 ≥4.0)
    HER2 negativeIHC 0 (no staining or faint/incomplete staining in ≤10% of cells) OR IHC 1+ (faint/barely perceptible incomplete membrane staining in >10% of cells) OR ISH negative per copy number/ratio thresholds
    inv-14: Clinical terms
    UnresectableUnable to be removed with surgery
    Progressive Disease (PD)

    Background

    Datroway (datopotamab deruxtecan-dlnk) is a Trop-2-directed antibody-drug conjugate with a topoisomerase inhibitor payload. It is indicated for adults with unresectable or metastatic disease per the product labeling, including use for specified breast cancer and certain EGFR-mutated non–small cell lung cancer indications.

    Revision History

    2026-02-20Annual reviewLatest

    Wording and formatting criteria changes; ICD-10-CM range for C50 updated to include C50.A0–C50.A2 (added to existing range C50.011–C50.929).

    2025-09-24Coding update

    Removed HCPCS C9174 and J9999 effective 2025-09-30 and added J9011 effective 2025-10-01 as the HCPCS code for Datroway.

    2025-08-15Material addition
    Policy Summary
    PayerAnthem
    PolicyDatroway (datopotamab deruxtecan-dlnk) — Medical Drug Clinical Criteria
    Policy CodePolicy CC-0279
    Change TypeAdded EGFR‑mutated NSCLC indicationcoding updates
    Effective Date03/26/2026
    Last ReviewFeb 20, 2026
    Next Review Date
    Key ActionObtain prior authorization and submit documentation showing diagnosis, HER2 and/or EGFR biomarker results, and required prior therapies.
    SourceLink
    On This Page
    Coverage CriteriaCovered Regimens (per label)CodingProvider Actions & RequirementsLine of Therapy RequirementsBiomarker & Testing RequirementsDefinitionsBackgroundRevision History
  1. Provide detailed prior treatment history confirming prior endocrine‑based therapy and prior chemotherapy for unresectable or metastatic disease (agents, dates, responses).
  2. Documentation Required

    NSCLC Documentation

    For NSCLC requests, provide documentation of disease extent and molecular testing and prior systemic therapy.

    • Confirm locally advanced or metastatic NSCLC and presence of an EGFR mutation (test report).
    • Document prior EGFR‑directed therapy (agent and dates) and prior platinum‑based chemotherapy (agent and dates).
    Step Therapy

    Prior Therapy Requirements

    Approval for the breast cancer and NSCLC indications requires prior therapies as a condition of coverage.

    • Breast cancer: patient must have received prior endocrine‑based therapy AND prior chemotherapy for unresectable or metastatic HR+ HER2‑negative disease.
    • NSCLC: patient must have received prior EGFR‑directed therapy AND prior platinum‑based chemotherapy for locally advanced or metastatic EGFR‑mutated disease.
    Prior therapy requirement
    Member must have received prior EGFR-directed therapy and platinum-based chemotherapy
    Cancer that is growing, spreading, or getting worse
    Refractory DiseaseIllness or disease that does not respond to treatment

    Added FDA indication for EGFR-mutated locally advanced or metastatic NSCLC for individuals with prior EGFR-directed and platinum-based chemotherapy; coding reviewed and ICD-10-CM codes C33 and C34.00–C34.92 added.

    2025-05-27Coding update

    Removed HCPCS NOC C9399 effective 2025-06-30 and added C9174 effective 2025-07-01; ICD-10-CM codes C50.011–C50.929, Z17.411, and Z92.21 were added.

    2025-02-21Select review and coding update

    New clinical criteria document for Datroway added; HCPCS NOC C9399, J9999, and diagnosis pend codes were added during coding review.